Policy changes at SAMHSA, DEA are needed to increase access to medications for opioid use disorder

BCHC provided comments to SAMHSA’s Medications for the Treatment of Opioid Use Disorder notice of proposed rulemaking. Comments focused on highlighting existing rules that perpetuate stigma and create barriers for individuals diagnosed with an opioid use disorder. BCHC also strongly supports making permanent the flexibility for the initiation of buprenorphine via telehealth visits.